Systemic Lupus Erythematosus (SLE) is associated with increased risk for accelerated
atherosclerosis and cardiovascular (CV) events including coronary heart disease …

Dysregulation of lymphocyte function, accumulation of autoantibodies and defective
clearance of circulating immune complexes and apoptotic cells are hallmarks of systemic …

Background and aims Chloroquine (CQ) and hydroxychloroquine (HCQ) are widely used in
patients with rheumatic diseases, but their effects on the cardiovascular system remain …

Systemic lupus erythematosus (SLE) carries a significant risk of cardiovascular disease
(CVD). The prevalence of premature CVD is especially noteworthy because it occurs in …

Introduction The aim of this study was to evaluate the proportion of patients with Systemic
Lupus Erythematosus (SLE) who did not met the WHO recommendations for physical activity …

Introduction The systemic inflammatory nature of systemic lupus erythematosus (SLE) is well
patent not only in the diverse clinical manifestations of the disease but also in the increased …

Patients with inflammatory rheumatic diseases often need orthopaedic surgery due to joint
involvement. Total hip replacement and total knee replacement are frequent surgical …

Background Low C3 and lupus anticoagulant (LAC) are known risk factors for thrombosis in
SLE. We evaluated the association between C4d products deposited on platelets (PC4d) …

Prolonged remission (PR), defined as a 5-year consecutive period of no disease activity
based on SLEDAI-2K, has been reported to be associated with a lower damage accrual over …

There is a well-known increased risk for cardiovascular disease that contributes to morbidity
and mortality in systemic lupus erythematosus (SLE). Major adverse cardiovascular events …